Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain.
Maria CeveyJaime Calvo AlénCarlos CrespoÁngel Robles-MarhuendaLee SmolenJosefina Cortés-HernándezPublished in: ClinicoEconomics and outcomes research : CEOR (2019)
The introduction of belimumab SC shows direct savings for the Spanish NHS. These savings could contribute to sustainability and decision-making.